Imunon (NASDAQ:IMNN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Imunon (NASDAQ:IMNN) in a report released on Wednesday,Benzinga reports. D. Boral Capital currently has a $29.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Imunon in a research report on Thursday, December 19th.

Imunon Stock Up 5.4 %

NASDAQ:IMNN opened at $0.92 on Wednesday. The stock’s 50-day simple moving average is $0.89 and its 200 day simple moving average is $0.96. The firm has a market capitalization of $13.33 million, a PE ratio of -0.49 and a beta of 2.03. Imunon has a twelve month low of $0.53 and a twelve month high of $3.65.

Hedge Funds Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC raised its position in Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.